Athira Pharma Inc (ATHA NASDAQ) stock market data APIs
$0.3829
-0.03(-7.8%)
as of September 15, 2025
Try our APIs with
free plan!
Athira Pharma Inc Financial Data Overview
Price chart is built with
Anychart
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Prev. Close
0.3829
Open
0.3558
High
0.3861
Low
0.3518
52 wk Range
0.22-0.826
Market Cap
15 149 K
Shares Outstanding
39 439 K
EPS
-0.18
Beta
3.016
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Athira Pharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Athira Pharma Inc data using free add-ons & libraries
Get Athira Pharma Inc Fundamental Data
Athira Pharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -56 915 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Athira Pharma Inc News
New
Athira pharma announces 10-for-1 reverse stock split
* Athira Pharma (NASDAQ:ATHA [https://seekingalpha.com/symbol/ATHA]) will effect a 10-for-1 reverse stock split of Athira’s issued and authorized common stock. * The reverse stock split will bec...
Athira Pharma Announces Reverse Stock Split
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecule...
Athira Pharma reports positive Phase 1 results for ALS drug candidate
BOTHELL, Wash. - Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biotech with strong liquidity ratios and more cash than debt according to InvestingPro data, presented results from its Phase 1 cli...
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
